Prof.Mary Jande Publications

  1. Indomethacin a potential trypanocide, project third year B.Pharm (1979).
  2. Determination of the contribution of Cytoplasmic membrane to the calcium antagonistic action of Verapamil, cinnarizine and Trifluoperazine – Thesis presented to University of Manchester for the degree of MSc. (1984).
  3. Jande and Sharma The effect of cupric sulphate on compound 48/80 and concanavalin – A induced release of histamine from rate peritoneal mast cells. Brit. J. Pharmacol. 1968, 570 p.
  4. Jande and Sharma Inhibition of calcium ionophore (A, 23187) induced histamine release from rate peritoneal mast cell by copper and Verapamil, Irish Journal of Medical Sciences 1987, 156 10, 299.
  5. Jande and Sharma Reversal of histamine release inhibitory effect of copper by lyphospha tidyl choline, Irish Journal of Medical Science, 1988, 157, 1, 23.
  6. Jande and Sharma: A comparison of copper with phenothiazines for erythrocyte stabilizing effect. , Irish J. Med. Sci. 1988, 157, 1, 25.
  7. Jande and Sharma A probe into histamine release inhibitory mechanism of copper using 45Ca-, Irish J. Med. Sci. 1988 Vol. 157, No. 5, 170.
  8. Sharma and Jande. Inhibition of mast cell histamine release by copper, Archives Internationals de Pharmacoldynamie at de Therapie Vol. 299, No ½ May/June, 1989.
  9. Copper: A novel inhibitor of histamine releases from rate peritoneal mast cells – Thesis presented to University of Dublin for the degree of PhD (1985).
  10. Adbi, Gustafson, DehlBertilsson, Massele A.Y., and Jande, Debrisoquine phenotype and genotype on black African, Journal de Pharmacologie Clinique et de Theraputique – 1st Congress of the European Association for Clinical Pharmacology and Therapeutics 27 – 30 September, 1995.
  11. Karin, Massele, Jande, ALM et al Bantu Tanzanian have a decreased capacity to metabolize Omeprazole and mephenytoin in relation to their CYP2C19 genotype, , Clinical Pharmacology and Therapeutics Volume 64 1998, 64:391 - 401
  12. AgnetaWennerholm, Inger Johansson, Amos Massele, Mary Jande at el Decreased capacity for Debrisoquine metabolism among black Tanzanian: Analyses of the CYP2D6 genotype and phenotype: Pharmacogenetics 1999, 9.
  13. M.B. Jande, O. Ngassapa M.A, and I.O. Kibwage. Quality of sulphadoxine/pyrimethamine tablets marketed in Dar es Salaam, Tanzania: East and Central African Journal of Pharmaceutical Sciences – 3(2000) 20 – 24.
  14. Chambuso MHS, Haule AF, Jande M, Ngassapa O, Kagashe G, Kalokola F, and Joshua R: Rescheduling of list of Human drugs, Drug Utilization and Pharmacogenetics, December, 2004.
  15. M. Auton, Z. Berege, F. Damian, M. Jande, MJ. Temu, E. Lupaya, C. Makwaya, V. Mugoyela. J. Muhume, S Mung’ong’o, C. Mwaifani, F. Nicolaus, G. Rimoy and R.Shija.Medicine Prices in Tanzania. prices/January 2006.
  16. Cristina Rodriguez Antona, Mary Jande, Anders Rane and MagrusIngelmanSundber Identification and phenotype characterization of two CYP3A haplotype causing different enzymatic capacity in fetal liver. Clinical Pharmacology and Therapeutics 2005, 77: 259 – 70.
  17. O.D. Ngassapa, M.B. Jande, M.H.S. Chambuso, J.G. Sayi, V.P. Manyanga Betel nut (ERECA Nut) Chewing: Knowledge attitude and practice by residents of Dar es Salaam, Tanzanian Medical Journal 20:2: June 2005: 15 - 19
  18. Tashinga E. Bapiro, Jane Sayi, Julia Hasler, Mary Jande, Gerald Rimoy, Amos Massele, Collen M Artemisinin and Thiabendazole are potent inhibitors of cytochrome P450 IA2 (CYPIA2) activity in humans: .Masimirembwa. European J. Clin. Pharmacol (2005) 61:755 – 761.
  19. Mirghani RA, Sayi J. Aklilu E, Allqvist A. Jande M.Wennerholm A. Ericksen J. Herben VMM, Jones BC, Gustafson LL, Bertisson L.CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians who have lower total CYP3A activity compared to a Swedish population, Pharmacogenet Genomics 2006, 16: 637-45.
  20. Nsimba S.E.D and Jande M.B. Household storage of pharmaceuticals and Dispensing Practices in Drug stores and ordinary Retail Shops in Rural Areas of Kibaha District—Tanzania. The East and Central African Journal of Pharmaceutical Sciences: 2006: 9; (3) 74-80.
  21. F. Josephson, A. Allqvist, M. Janabi, J.Sayi, E. Aklilu, M. Jande, M. Mahindi, J. Burhenne, Y. Bottiger, L.L. Gustafson, W.E. Haefeli and L. Bertilsson.CYP3A5 Genotype have an Impact on the metabolism of HIV Protease Inhibitor Saquinavir. Clinical Pharmacology & Therapeutics (2007)81, 708-712.
  22. Diczfalusy, Ulf: Miura, Jun; Roh, Hyung-Keun; Mirghani, Rajaa A.; Sayi, Jane; Larsson, Hanna; Bodin, Karl g.; Allqvist, Annika; Jande Mary; Kim, Jong-Wook; Aklilu, Eleni; Gustafsson, Lars L; BertilssonLeif, 4 [beta]-Hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. Pharmacogenetics and Genomics: March 2008-Volume 18- Issue 3-pp 201-208.
  23. Kiyeti Hauli, David Ndetei, Mary Jande and Rodrick Kabangila. The Prevalence of Substance Use Among Psychiatric Patients: The case study of Bugando Medical Centre Mwanza (Northern Tanzania) Substance abuse Volume 32, Issue 4, 2011 pg 238-241
  24. Jande M.B.Muhereza A, Kongola G.W and Rimoy G. Poor management of tuberculosis in inmates within Dar es Salaam prisons. M. B. East and Central African Journal of Pharmaceutical Sciences. Volume 14, No. 1 2011 pg 16-22.
  25. Jande M, G. Kongola and J.W. Mwangi. Drug prescribing pattern in two hospitals in Mwanza, North west Tanzania. Central African Journal of Pharmaceutical Sciences. Volume 15, 2012 pg 63- 68.
  26. Mary Jande, Antony Liwa, Gilbert Kongola & Mary Justin- Temu. Assessment of Patient Satisfaction with Pharmaceutical Services in Hospital Pharmacies in Dar es salaam, Tanzania.East and Central African Journal of Pharmaceutical Sciences Vol. 16 (2013) 24-30.
  27. M. Jande, E. Magelewanya, G.W. Kongola and J.W Mwangi. Home management of febrile Children Under-Five Years in Kahama Districts, North- Western Tanzania. East and Central African Journal of Pharmaceutical Sciences Vol. 16 2013, pg 54-58.
  28. M. Jande, G. Kongola, A. Liwa, M. Justin-Temu and J.W Mwangi. Community Awareness of Adverse Effects of Nonsteroidal Anti-inflammatory Drugs in Ilala Municipality, Dar es Salaam. Central African Journal of Pharmaceutical Sciences. Volume 16, 2013 pg 83- 87.
  29. Jande Mary, Kongola G., Kalluvya S., Majinge C., Kapiga S., Hauli AgnesKiyeti& Kidenya B. Association between HIV infection and the over 18 years old people who use drugs in Mwanza urban, Tanzania. Int. j Res Health Science [internet] July – Sept 2014 Vol-2(3); 740-9.
  30. Hauli K A, Kongola G W, Kalluvya S E, Jande M B, Majinge C Ret al. Sy03-1-3isam fellowship prevalence of hiv infection among the over 18 year old substance abusers in Mwanza urban, Tanzania.Alcohol and alcoholism (Oxford, Oxfordshire), 2014; 49 Suppl 1 doi:10.1093/alcalc/agu052.12
  31. M. Jande, M.Chaula, G. Kongola & K.Hamasaki. Adherence to antiretroviral Therapy in HIV- Infected Children and adolescents Attending Sekou Toure Care and Treatment Clinic in Mwanza, Tanzania. International Journal of Contemporary Medical Research (IJCMR)Volume 2: Issue 4, 2015 pg 804-810
  32. Seni, Peter Hamisi, Vitus Silago, Stephene Eliatosha Mshana, Mary Jande. Microbial contamination of traditional liquid herbal medicinal products marketed in Mwanza city: magnitude and risk factors, Pan African Medical Journal. 2016; 23:65 doi:10.11604/ Walther et al
  33. Linus Muhando, Mary Jande, Antony Liwa, Stanley Mwita and Karol Marwa. Public Awareness and Identification of counterfeit Drugs in Tanzania: A view on Antimalarial drugs. Advances in Public Health 2016 Advances in Public Health Volume 2016 (2016), Article ID 6254157, 8 pages
  34. Martha Mushi, Benedictor Masewa, Mary Jande, Mariam Mirambo and Stephen Mshana. Prevalence and factors associated with over-the-counter use of antifungal agents in Mwanza City, Tanzania. Tanzania Journal of Health ResearchDoi: Volume 19, Number 1January 2017